SYRACUSE BIOPHARMA
Syracuse Biopharma was formed in 2017 by Eureka Therapeutics to commercialize Eureka’s proprietary TCR-mimic and antibody-TCR ARTEMIS® programs in China and the ASEAN countries. Syracuse’s clinical programs include Eureka’s anti-AFP ARTEMIS® program for the treatment of hepatocellular carcinoma (HCC), the predominant type of liver cancer, which is currently in a Phase I/II clinical trial in the United States.
SYRACUSE BIOPHARMA
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2017-01-01
Address:
Hong Kong, Hong Kong Island, Hong Kong
Country:
Hong Kong
Status:
Active
Similar Organizations
Genevide
Genevide is a biotech company that specializes in gene research and development.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
More informations about "Syracuse Biopharma"
JW Therapeutics Acquires Syracuse Biopharma and License to
Jul 20, 2020 Shanghai, China and Emeryville, California, July 20, 2020 – JW Therapeutics, a clinical stage biopharmaceutical company focused on developing, manufacturing and …See details»
JW Therapeutics Acquires Syracuse Biopharma and Its In-Licenses …
Jul 20, 2020 Syracuse Biopharma was formed in 2017 by Eureka Therapeutics to commercialize Eureka’s proprietary TCR-mimic and antibody-TCR ARTEMIS® programs in China and the …See details»
History - JW Therapeutics
Acquired Syracuse Biopharma. Jun. Suzhou site obtained drug manufacturing license. Nov. Listed on the main board of the Hong Kong Exchanges and Clearing Limited, stock code 2126.HK. …See details»
JW Therapeutics Acquires Syracuse Biopharma and License to …
Jul 20, 2020 Syracuse Biopharma was formed in 2017 by Eureka Therapeutics to commercialize Eureka’s proprietary TCR-mimic and antibody-TCR ARTEMIS ® programs in China and the …See details»
JW Therapeutics acquires Syracuse, licenses Eureka's
Jul 20, 2020 Eureka established Syracuse Biopharma in 2017 to commercialize its TCR-mimic and antibody-TCR Artemis programs in China and ASEAN regions. Terms of the deal were not disclosed in a July 20 news release. Eureka …See details»
Syracuse Biopharma - Ownership and Business Overview - Mergr
Jul 20, 2020 Syracuse’s clinical programs include Eureka’s anti-AFP ARTEMIS® program for the treatment of hepatocellular carcinoma (HCC), the predominant type of liver cancer, which is …See details»
JW Therapeutics acquires Syracuse Biopharma - Crunchbase
Jul 20, 2020 Syracuse Biopharma Syracuse Biopharma formed to commercialize Eureka's proprietary TCR-mimic and antibody-TCR ARTEMIS programs. Acquiring Organization: JW …See details»
Syracuse Biopharma - Crunchbase
Syracuse Biopharma formed to commercialize Eureka's proprietary TCR-mimic and antibody-TCR ARTEMIS programs.See details»
JW Therapeutics Acquires Syracuse Biopharma and Its in-Licenses …
Jul 20, 2020 SHANGHAI and EMERYVILLE, Calif., July 20, 2020 /PRNewswire/ -- JW Therapeutics Acquires Syracuse Biopharma and Its in-Licenses With Eureka Therapeutics' …See details»
JW Therapeutics acquires Syracuse and license to Eureka’s solid …
JW Therapeutics announced the acquisition of Syracuse Biopharma (Hong Kong) Limited, which includes the license for Eureka Therapeutics’ ARTEMIS antibody TCR and solid tumor …See details»
JW Therapeutics Acquires Syracuse Biopharma - FinSMEs
Jul 26, 2020 JW Therapeutics, a clinical stage biopharmaceutical company focused on developing, manufacturing and commercializing cell therapies for patients in China, acquired …See details»
JW Therapeutics Acquires Syracuse Biopharma and Its in-Licenses …
Jul 20, 2020 SHANGHAI and EMERYVILLE, Calif., July 20, 2020 /PRNewswire/ -- JW Therapeutics, a clinical stage biopharmaceutical company focused on developing, ...See details»
Syracuse Biopharma - Products, Competitors, Financials, …
Syracuse Biopharma was formed in 2017 by Eureka Therapeutics to commercialize Eureka’s proprietary TCR-mimic and antibody-TCR ARTEMIS® programs in China and the ASEAN …See details»
JW Therapeutics Acquires Syracuse Biopharma and License to …
Jul 27, 2020 JW Therapeutics, a clinical stage biopharmaceutical company focused on developing, manufacturing and commercializing cell therapies for patients in China, today …See details»
JW Therapeutics Acquires Syracuse Biopharma and License to
Jul 20, 2020 Syracuse Biopharma was formed in 2017 by Eureka Therapeutics to commercialize Eureka’s proprietary TCR-mimic and antibody-TCR ARTEMIS ® programs in China and the …See details»
JW Therapeutics Acquires Syracuse Biopharma and Its in-Licenses …
Jul 21, 2020 JW Therapeutics Acquires Syracuse Biopharma and Its in-Licenses With Eureka Therapeutics’ Solid Tumor Technologies in China. PR Newswire July 20, 2020 — 21:33 CST …See details»
JW Therapeutics - Funding, Financials, Valuation & Investors
Which types of acquisition does this organization make most frequently? Show . Acquiree Name . Announced Date . Price . Transaction Name . Syracuse Biopharma . Jul 20, 2020 — Syracuse …See details»
Lotte Biologics Intends to Become a Global CDMO - PROCESS …
Feb 14, 2023 Lotte Biologics has acquired the Syracuse plant in the United States from Bristol Myers Squibb Co. and now plans to expand it by adding ADC contract manufacturing services …See details»
Syracuse Biopharma - Updates, News, Events, Signals & Triggers
Syracuse Biopharma formed to commercialize Eureka's proprietary TCR-mimic and antibody-TCR ARTEMIS programs.See details»